Administration of <i>Akkermansia muciniphila</i> Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice.

Bian X, Wu W, Yang L, Lv L, Wang Q, Li Y, Ye J, Fang D, Wu J, Jiang X, Shi D, Li L. · 2019

Read Administration of <i>Akkermansia muciniphila</i> Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. by Bian X, Wu W, Yang L, Lv L, Wang Q, Li Y, Ye J, Fang D, Wu J, Jiang X, Shi D, Li L. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6779789.txt.

Introduction

Bian and co-authors tested a gut bacterium, Akkermansia muciniphila, against ulcerative colitis in mice. This bacterium is linked to a healthy gut lining, but its role in colitis was unknown. Twenty-four male mice received the bacterium or a salt solution daily for 14 days. Colitis was triggered with a chemical, DSS, in their drinking water.

Treated mice fared better on every measure. They lost less weight, kept longer colons, and scored lower on tissue damage. Their gut barrier worked better too. Inflammatory signals in blood and tissue fell, including TNF-alpha and several interleukins. The bacterium also reshaped the gut community, raising its diversity. Higher diversity tracked with lower inflammation.

Catalog record

CREATORBian X, Wu W, Yang L, Lv L, Wang Q, Li Y, Ye J, Fang D, Wu J, Jiang X, Shi D, Li L.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE76 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6779789

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Administration of Akkermansia muciniphila Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice By Xiaoyuan Bian, Wenrui Wu, Liya Yang, Longxian Lv, Qing Wang, Yating Li, Jianzhong Ye, Daiqiong Fang, Jingjing Wu, Xianwan Jiang, Ding Shi, Lanjuan Li Published in: Frontiers in Microbiology DOI: 10.3389/fmicb.2019.02259 ABSTRACT Inflammatory bowel diseases (IBDs) develop as a result of complex interactions among genes, innate immunity and environmental factors, which are related to the gut microbiota. Multiple clinical and animal data have shown that Akkermansia muciniphila is associated with a healthy mucosa. However, its precise role in colitis is currently unknown. Our study aimed to determine its protective effects and underlying mechanisms in a dextran sulfate sodium (DSS)-induced colitis mouse model. Twenty-four C57BL/6 male mice were administered A. muciniphila MucT or phosphate-buffered saline (PBS) once daily by oral gavage for 14 days. Colitis was induced by drinking 2% DSS from days 0 to 6, followed by 2 days of drinking normal water. Mice were weighed daily and then sacrificed on day 8. We found that A. muciniphila improved DSS-induced colitis, which was evidenced by reduced weight loss, colon length shortening and histopathology scores and enhanced barrier function. Serum and tissue levels of inflammatory cytokines and chemokines (TNF-α, IL1α, IL6, IL12A, MIP-1A, G-CSF, and KC) decreased as a result of A. muciniphila administration. Analysis of 16S rDNA sequences showed that A. muciniphila induced significant gut microbiota alterations. Furthermore, correlation analysis indicated that pro-inflammatory cytokines and other injury factors were negatively associated with Verrucomicrobia, Akkermansia, Ruminococcaceae, and Rikenellaceae, which were prominently abundant in A. muciniphila-treated mice. We confirmed that A. muciniphila treatment could ameliorate mucosal inflammation either via microbe-host interactions, which protect the gut barrier function and reduce the levels of inflammatory cytokines, or by improving the microbial community. Our findings suggest that A. muciniphila may be a potential probiotic agent for ameliorating colitis. INTRODUCTION Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn’s disease (CD), have developed into a global scourge with an increasing incidence and prevalence worldwide in the last 50 years (Kaplan, 2015; Parada Venegas et al., 2019). IBDs were convincingly shown to develop as a result of complex interactions among genes, innate immunity and environmental factors (Parada Venegas et al., 2019). Intriguingly, gut microbiota, relevant to the mucosal immunity and host metabolism, is likely the most crucial environmental factors in IBD pathogenesis. Multiple studies have confirmed that gut microbiota plays an key role in the severity and progression of colitis in IBD patients (Marion-Letellier et al., 2016). Although there is a strong linkage between the gut microbiota and IBDs, the exact mechanisms of the interactions are still unclear (Von Schillde et al., 2012). Dextran sulfate sodium (DSS) administration is a chemical method to induce colitis, which results in similar key clinical and pathological features of IBDs to those in humans (Okayasu et al., 1990). DSS administration is believed to impair intestinal epithelial cells due to its toxicity. Consequently, the destroyed barrier function allows the immune cells to be exposed to antigens (e.g., microbes), resulting in a subsequent immune response (Wirtz et al., 2017). Based on the properties of colitis, this method is suitable to investigate the impacts of the intestinal microbiota on colitis progression (Hudcovic et al., 2001; Hernandez-Chirlaque et al., 2016). For instance, a recent study revealed that some specific bacterial taxa were present in the crypts due to the functions of NOD-like receptor protein 6 (NLRP6), which are associated with the severity of colitis (Elinav et al., 2011). Moreover, DSS-induced colitis has been broadly applied as a model for its simplicity and reproducibility. Akkermansia muciniphila has been identified as the representative of the phylum Verrucomicrobia and represents 1–5% of the human intestinal microbial community (Collado et al., 2007; Derrien et al., 2008). A. muciniphila, as a gram-negative and strictly anaerobic bacterium, tends to widely colonize the nutrient-rich intestinal mucus layer (Derrien et al., 2004). Studies have demonstrated that A. muciniphila is able to degrade host mucin into various products (e.g., short chain fatty acids) to regulate host biological functions, such as glucose and lipid metabolism, and to modulate the expression of mucus-related genes, which participate in host immune responses (Derrien et al., 2004, 2011). A. muciniphila was confirmed to exert a major role in maintaining gut barrier function, host metabolism and other biological functions through interactions between intestinal microbes and host in metabolic disorders (Everard et al., 2013). Moreover, Png et al. (2010) observed that the abundance of A. muciniphila was markedly reduced in patients with IBD compared with the abundance in controls, indicating that A. muciniphila may be related to the health of the intestinal mucosa. These findings indicate that A. muciniphila might play a crucial role in protecting against intestinal injury, which occurs in IBD. However, the precise protective roles A. muciniphila plays and the underlying mechanisms during the progression of the disease are not completely understood. Therefore, our study aimed to investigate the protective effects of A. muciniphila against colitis and the potential underlying mechanisms in a DSS-induced colitis mouse model. MATERIALS AND METHODS Bacterial Strains and Growth Conditions A. muciniphila MucT (ATTC BAA835) was cultured in a basal mucin-based brain heart Infusion medium (OXOID, Thermo Fisher Biochemicals Ltd., Baesingstoke, United Kingdom) at 37°C for 48 h under an anaerobic environment, as previously reported (Derrien et al., 2004). The cultures were centrifuged (8000 × g for 10 min at 4°C), washed with sterile phosphate buffer saline (PBS, pH 7.2) twice, and then concentrated to the final concentration of 1.5∗1010 colony-forming units (CFU)/ml by measuring absorbance at 630 nm (O.D. range from 0.6 to 0.8) for further use. The experiments described above were performed under strict anaerobic conditions. Animals All animal experiments were reviewed and approved by the Local Committee of Animal Use and Protection. Specific pathogen-free (SPF) male C57BL/6 mice aged 5 weeks were initially obtained from Shanghai Laboratory Animal, Co., Ltd. (SLAC). All mice were conventionally raised under SPF conditions, and the experiments were performed when the mice were 6–7 weeks old. DSS-Induced Colitis and Experimental Design Twenty-four mice were randomly assigned to three groups (n = 8 each): normal control group (CP group), experimental model group (DP group) and A. muciniphila group (AKK group). Mice in the AKK group (DSS + A. muciniphila) were administered 0.2 ml A. muciniphila (3∗109 CFU) once daily by oral gavage for 14 days (day -7 to day 7, Figure 1A), while mice in the DP group (DSS + PBS) and the CP group (Water + PBS) were given equal amounts of anaerobic sterile PBS. On day 0, the mice in the AKK group and the DP group were administered 2% (wt/vol) DSS (molecular weight: 36,000–50,000; MP Biomedicals, cat. no. 0216011080) dissolved in drinking water for 7 days (days 0–6) followed by 2 days of normal water. New fresh DSS solutions were prepared every 2nd day. Meanwhile, the mice in the CP group were given normal drinking water for 9 days (days 0–8). Mouse weights were recorded throughout the experiment and fecal samples were collected on days 0 and 8. At the end of the experiment (day 8), all mice were humanely euthanized after serum and colon segment collection (Figure 1A). Feces and serum were stored at −80°C until analysis. Colon

Read the complete text